3D Pseudocontinuous Arterial Spin-Labeling MR Imaging in the Preoperative Evaluation of Gliomas

References

1. 1.↵
   2. Schwartzbaum JA,
   3. Fisher JL,
   4. Aldape KD, et al

   . Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006;2:494–503 doi:10.1038/ncpneuro0289 pmid:16932614

   CrossRefPubMed
2. 2.↵
   2. Weller M,
   3. van den Bent M,
   4. Hopkins K, et al

   ; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014;15:e395–e403 doi:10.1016/S1470-2045(14)70011-7 pmid:25079102

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Soffietti R,
   3. Baumert BG,
   4. Bello L, et al

   ; European Federation of Neurological Societies. Guidelines on the management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 2010;17:1124–33 doi:10.1111/j.1468-1331.2010.03151.x pmid:20718851

   CrossRefPubMed
4. 4.↵
   2. Roy B,
   3. Gupta RK,
   4. Maudsley AA, et al

   . Utility of multiparametric 3-T MRI for glioma characterization. Neuroradiology 2013;55:603–13 doi:10.1007/s00234-013-1145-x pmid:23377234

   CrossRefPubMed
5. 5.↵
   2. Nguyen TB,
   3. Cron GO,
   4. Perdrizet K, et al

   . Comparison of the diagnostic accuracy of DSC- and dynamic contrast-enhanced MRI in the preoperative grading of astrocytomas. AJNR Am J Neuroradiol 2015;36:2017–22 doi:10.3174/ajnr.A4398 pmid:26228886

   Abstract/FREE Full Text
6. 6.↵
   2. Knopp EA,
   3. Cha S,
   4. Johnson G, et al

   . Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–98 doi:10.1148/radiology.211.3.r99jn46791 pmid:10352608

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Law M,
   3. Yang S,
   4. Babb JS, et al

   . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–55 pmid:15140713

   Abstract/FREE Full Text
8. 8.↵
   2. Furtner J,
   3. Schöpf V,
   4. Schewzow K, et al

   . Arterial spin-labeling assessment of normalized vascular intratumoral signal intensity as a predictor of histologic grade of astrocytic neoplasms. AJNR Am J Neuroradiol 2014;35:482–89 doi:10.3174/ajnr.A3705 pmid:23945226

   Abstract/FREE Full Text
9. 9.↵
   2. Rau MK,
   3. Braun C,
   4. Skardelly M, et al

   . Prognostic value of blood flow estimated by arterial spin labeling and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas. J Neurooncol 2014;120:557–66 doi:10.1007/s11060-014-1586-z pmid:25154323

   CrossRefPubMed
10. 10.↵
    2. Fudaba H,
    3. Shimomura T,
    4. Abe T, et al

    . Comparison of multiple parameters obtained on 3T pulsed arterial spin-labeling, diffusion tensor imaging, and MRS and the Ki-67 labeling index in evaluating glioma grading. AJNR Am J Neuroradiol 2014;35:2091–98 doi:10.3174/ajnr.A4018 pmid:24994829

    Abstract/FREE Full Text
11. 11.↵
    2. Kim HS,
    3. Kim SY

    . A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol 2007;28:1693–99 doi:10.3174/ajnr.A0674 pmid:17885229

    Abstract/FREE Full Text
12. 12.↵
    2. Chawla S,
    3. Wang S,
    4. Wolf RL, et al

    . Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007;28:1683–89 doi:10.3174/ajnr.A0673 pmid:17893221

    Abstract/FREE Full Text
13. 13.↵
    2. Warmuth C,
    3. Gunther M,
    4. Zimmer C

    . Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228:523–32 doi:10.1148/radiol.2282020409 pmid:12819338

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Kim MJ,
    3. Kim HS,
    4. Kim JH, et al

    . Diagnostic accuracy and interobserver variability of pulsed arterial spin labeling for glioma grading. Acta Radiol 2008;49:450–57 doi:10.1080/02841850701881820 pmid:18415790

    CrossRefPubMed
15. 15.↵
    2. Wolf RL,
    3. Wang J,
    4. Wang S, et al

    . Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging 2005;22:475–82 doi:10.1002/jmri.20415 pmid:16161080

    CrossRefPubMed
16. 16.↵
    2. Furtner J,
    3. Bender B,
    4. Braun C, et al

    . Prognostic value of blood flow measurements using arterial spin labeling in gliomas. PLoS One 2014;9:e99616 doi:10.1371/journal.pone.0099616 pmid:24911025

    CrossRefPubMed
17. 17.↵
    2. Qiao XJ,
    3. Ellingson BM,
    4. Kim HJ, et al

    . Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma. AJNR Am J Neuroradiol 2015;36:672–77 doi:10.3174/ajnr.A4196 pmid:25542879

    Abstract/FREE Full Text
18. 18.↵
    2. Wong EC

    . New developments in arterial spin labeling pulse sequences. NMR Biomed 2013;26:887–91 doi:10.1002/nbm.2954 pmid:23733501

    CrossRefPubMed
19. 19.↵
    2. Garcia DM,
    3. De Bazelaire C,
    4. Alsop D

    . Pseudo-continuous flow driven adiabatic inversion for arterial spin labeling. Proc Int Soc Magn Reson Med 2005;13:37
20. 20.↵
    2. Fernández-Seara MA,
    3. Edlow BL,
    4. Hoang A, et al

    . Minimizing acquisition time of arterial spin labeling at 3T. Magn Reson Med 2008;59:1467–71 doi:10.1002/mrm.21633 pmid:18506806

    CrossRefPubMed
21. 21.↵
    2. Roy B,
    3. Awasthi R,
    4. Bindal A, et al

    . Comparative evaluation of 3-dimensional pseudocontinuous arterial spin labeling with dynamic contrast-enhanced perfusion magnetic resonance imaging in grading of human glioma. J Comput Assist Tomogr 2013;37:321–26 doi:10.1097/RCT.0b013e318282d7e2 pmid:23673999

    CrossRefPubMed
22. 22.↵
    2. Mayer A,
    3. Schneider F,
    4. Vaupel P, et al

    . Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. Int J Oncol 2012;41:1260–70 doi:10.3892/ijo.2012.1555 pmid:22825389

    CrossRefPubMed
23. 23.↵
    2. Schaffel R,
    3. Hedvat CV,
    4. Teruya-Feldstein J, et al

    . Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010;21:133–39 doi:10.1093/annonc/mdp495 pmid:20019090

    CrossRefPubMed
24. 24.↵
    2. Bottini A,
    3. Berruti A,
    4. Brizzi MP, et al

    . Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer 2005;12:383–92 doi:10.1677/erc.1.00945 pmid:15947110

    Abstract/FREE Full Text
25. 25.↵
    2. Jain R,
    3. Poisson LM,
    4. Gutman D, et al

    . Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology 2014;272:484–93 doi:10.1148/radiol.14131691 pmid:24646147

    CrossRefPubMed
26. 26.↵
    2. Lev MH,
    3. Ozsunar Y,
    4. Henson JW, et al

    . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas [corrected]. AJNR Am J Neuroradiol 2004;25:214–21 pmid:14970020

    Abstract/FREE Full Text
27. 27.↵
    2. Cha S,
    3. Tihan T,
    4. Crawford F, et al

    . Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266–73 pmid:15709123

    Abstract/FREE Full Text
28. 28.↵
    2. Fellah S,
    3. Caudal D,
    4. De Paula AM, et al

    . Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol 2013;34:1326–33 doi:10.3174/ajnr.A3352 pmid:23221948

    Abstract/FREE Full Text
29. 29.↵
    2. Kapoor GS,
    3. Gocke TA,
    4. Chawla S, et al

    . Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 2009;92:373–86 doi:10.1007/s11060-009-9880-x pmid:19357963

    CrossRefPubMed
30. 30.↵
    2. Whitmore RG,
    3. Krejza J,
    4. Kapoor GS, et al

    . Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007;107:600–09 doi:10.3171/JNS-07/09/0600 pmid:17886561

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Spampinato MV,
    3. Smith JK,
    4. Kwock L, et al

    . Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007;188:204–12 doi:10.2214/AJR.05.1177 pmid:17179366

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Jenkinson MD,
    3. Smith TS,
    4. Joyce KA, et al

    . Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006;48:703–13 doi:10.1007/s00234-006-0122-z pmid:16937145

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Hilario A,
    3. Ramos A,
    4. Perez-Nuñez A, et al

    . The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol 2012;33:701–07 doi:10.3174/ajnr.A2846 pmid:22207304

    Abstract/FREE Full Text
34. 34.↵
    2. Xu M,
    3. See SJ,
    4. Ng WH, et al

    . Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005;56:919–26 doi:10.1227/01.NEU.0000157957.67708.3E pmid:28184662

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Evans SM,
    3. Judy KD,
    4. Dunphy I, et al

    . Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177–84 doi:10.1158/1078-0432.CCR-04-1081 pmid:15623592

    Abstract/FREE Full Text
36. 36.↵
    2. Korkolopoulou P,
    3. Patsouris E,
    4. Konstantinidou AE, et al

    . Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas: associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 2004;30:267–78 doi:10.1111/j.1365-2990.2003.00535.x pmid:15175080

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Mashiko R,
    3. Takano S,
    4. Ishikawa E, et al

    . Hypoxia-inducible factor 1alpha expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image. J Neurooncol 2011;102:43–50 doi:10.1007/s11060-010-0292-8 pmid:20596750

    CrossRefPubMed
38. 38.↵
    2. Birner P,
    3. Piribauer M,
    4. Fischer I, et al

    . Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 2003;13:133–43 pmid:12744467

    PubMedWeb of Science
39. 39.↵
    2. Bekaert L,
    3. Valable S,
    4. Lechapt-Zalcman E, et al

    . [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging 2017;44:1383–92 doi:10.1007/s00259-017-3677-5 pmid:28315948

    CrossRefPubMed
40. 40.↵
    2. Fujiwara S,
    3. Nakagawa K,
    4. Harada H, et al

    . Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol 2007;30:793–802 pmid:17332917

    PubMedWeb of Science
41. 41.↵
    2. Zagzag D,
    3. Lukyanov Y,
    4. Lan L, et al

    . Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006;86:1221–32 doi:10.1038/labinvest.3700482 pmid:17075581

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Toth RK,
    3. Warfel NA

    . Strange bedfellows: nuclear factor, erythroid 2-like 2 (Nrf2) and hypoxia-inducible factor 1 (HIF-1) in tumor hypoxia. Antioxidants 2017;6:27 doi:10.3390/antiox6020027 pmid:28383481

    CrossRefPubMed
43. 43.↵
    2. Liu H,
    3. Cai Y,
    4. Zhang Y, et al

    . Development of a hypoxic radiosensitizer-prodrug liposome delivery DNA repair inhibitor Dbait combination with radiotherapy for glioma therapy. Adv Healthc Mater 2017;6:1601377 doi:10.1002/adhm.201601377 pmid:28371526

    CrossRefPubMed
44. 44.↵
    2. Law M,
    3. Young RJ,
    4. Babb JS, et al

    . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98 doi:10.1148/radiol.2472070898 pmid:18349315

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Deike K,
    3. Wiestler B,
    4. Graf M, et al

    . Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma. J Neurooncol 2016;126:463–72 doi:10.1007/s11060-015-1982-z pmid:26518541

    CrossRefPubMed